Iambic Therapeutics jumps 16% in Nasdaq debut after style="font-family:var(--ff-display);font-size:clamp(1.4rem,3vw,1.9rem);font-weight:800;letter-spacing:-.04em;line-height:1.2;margin-bottom:14px;color:var(--tx)"50M IPO

Iambic's successful IPO highlights growing investor confidence in AI-driven biotech, potentially accelerating innovation in cancer treatment. The post Iambic Therapeutics jumps 16% in Nasdaq debut after style="font-size:1rem;color:var(--t1);line-height:1.75;margin-bottom:20px;font-weight:300;padding:14px 18px;border-left:2px solid var(--blue);background:rgba(33,136,255,.06);border-radius:0 8px 8px 0"50M IPO appeared first on Crypto Briefing.